WenJun Jia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
WenJun Jia has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Wanwan Li
Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
2 shared publicationsXiao Chen
Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
2 shared publicationsChenxu Meng
Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
1 shared publicationChenyu Sun
Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
1 shared publicationJianzhong Zhang
Institute of AnHui Medical University
1 shared publicationLei Yang
Institute of AnHui Medical University
1 shared publication
Latest Publications
- Open Access
- 2 February 2024
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (2) , 1-16
Exploring CCL11 in breast cancer: unraveling its anticancer potential and immune modulatory effects involving the Akt-S6 signaling
Background: CCL11, a chemokine known for recruiting immune cells to the tumor microenvironment (TME), has an unclear role in the context of its expression, patient prognosis, and the presence of tumor-infiltrating immune cells (TILs) in breast cancer. Methods: The expression of CCL11 in invasive breast cancer (BRCA) was analyzed using TCGA database. Survival curve and Cox regression analysis determined the potential of CCL11 as an independent prognostic indicator. GSEA performed functional analysis on genes related to CCL11. CIBERSORT algorithm quantified the infiltration level of immune cells with varying CCL11 expression. Lastly, the correlation between CCL11 expression and anticancer drug sensitivity was examined. Immunohistochemistry (IHC) and qRT-PCR confirmed CCL11 expression in clinical tissue samples. The anti-tumor efficacy of CCL11 was investigated using CCK-8, plate formation, transwell assay, and Western blot. Results: CCL11 expression was elevated in BRCA tumor tissues compared to adjacent normal tissues. Recurrence-free survival (RFS) was longer in patients with high expression of CCL11. Enrichment and co-expression analyses revealed CCL11's association with numerous immune-related signaling pathways and genes. Validation studies confirmed high CCL11 expression in breast cancer tissues. In vitro experiments substantiated CCL11's anticancer effects in BRCA. Conclusion: CCL11 expression correlates with immune cell infiltration in breast cancer, indicating its potential as a prognostic biomarker for BRCA.
- 2 February 2024
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (2) , 1-16
Open AccessExploring CCL11 in breast cancer: unraveling its anticancer potential and immune modulatory effects involving the Akt-S6 signaling
Background: CCL11, a chemokine known for recruiting immune cells to the tumor microenvironment (TME), has an unclear role in the context of its expression, patient prognosis, and the presence of tumor-infiltrating immune cells (TILs) in breast cancer. Methods: The expression of CCL11 in invasive breast cancer (BRCA) was analyzed using TCGA database. Survival curve and Cox regression analysis determined the potential of CCL11 as an independent prognostic indicator. GSEA performed functional analysis on genes related to CCL11. CIBERSORT algorithm quantified the infiltration level of immune cells with varying CCL11 expression. Lastly, the correlation between CCL11 expression and anticancer drug sensitivity was examined. Immunohistochemistry (IHC) and qRT-PCR confirmed CCL11 expression in clinical tissue samples. The anti-tumor efficacy of CCL11 was investigated using CCK-8, plate formation, transwell assay, and Western blot. Results: CCL11 expression was elevated in BRCA tumor tissues compared to adjacent normal tissues. Recurrence-free survival (RFS) was longer in patients with high expression of CCL11. Enrichment and co-expression analyses revealed CCL11's association with numerous immune-related signaling pathways and genes. Validation studies confirmed high CCL11 expression in breast cancer tissues. In vitro experiments substantiated CCL11's anticancer effects in BRCA. Conclusion: CCL11 expression correlates with immune cell infiltration in breast cancer, indicating its potential as a prognostic biomarker for BRCA.
- Open Access
- 27 June 2022
- Published by Springer Nature in Research Square
The Expression and Prognostic Value of CCL19 in Breast Cancer
Background Breast cancer is the leading cause of cancer related death in women worldwide. Early diagnosis is the most effective way to reduce breast cancer mortality. Immune and tumor processes are closely related. This study aims to explore the mechanism of immune and potential biomarkers of breast cancer through bioinformatics. Objective First, differentially expressed genes (DEGs) were screened by consensus analysis of invasive breast cancer (BRCA) samples from The Cancer Genome Atlas (TCGA) database based on immune genes. Then, protein interaction (PPI) networks, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to narrow down the potential genes. Finally, expression analysis and prognostic analysis of hub genes were used to select reliable key genes to identify CCL19. Immunohistochemistry (IHC) was used to detect the differential expression of CCL19 in tumor tissues and adjacent tissues of breast cancer. Protein correlation analysis, signaling pathway analysis, immune infiltration analysis, gene co-expression analysis and drug sensitivity analysis of CCL19 were further used to explore the pathological clinical features and potential biological functions of CCL19. Results The expression of CCL19 was significantly increased in breast cancer. High expression of CCL19 correlates with tumor stage and predicts a better prognosis in breast cancer. The expression of CCL19 correlates with the levels of various tumor immune infiltrating cells (TILs). CCL19 has positive correlation with the expression of most immune-related genes, including immune activator, immunosuppressant, chemokine, chemokine receptor, and major histocompatibility complex (MHC) genes. Enrichment analysis showed that CCL19 was involved in immune-related pathways and PI3K-Akt signaling pathway. The above results indicate that CCL19 may modulate the prognosis of breast cancer through immune infiltration. CCL19 affects the sensitivity to chemotherapy and targeted therapy, which affects the sensitivity of TAK-715, KIN001-102 and 17-AAG. Conclusion CCL19 is overexpressed in breast cancer. CCL19 may serve as a promising biomarker for predicting breast prognosis and a candidate therapeutic target.
- 27 June 2022
- Published by Springer Nature in Research Square
Open AccessThe Expression and Prognostic Value of CCL19 in Breast Cancer
Background Breast cancer is the leading cause of cancer related death in women worldwide. Early diagnosis is the most effective way to reduce breast cancer mortality. Immune and tumor processes are closely related. This study aims to explore the mechanism of immune and potential biomarkers of breast cancer through bioinformatics. Objective First, differentially expressed genes (DEGs) were screened by consensus analysis of invasive breast cancer (BRCA) samples from The Cancer Genome Atlas (TCGA) database based on immune genes. Then, protein interaction (PPI) networks, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to narrow down the potential genes. Finally, expression analysis and prognostic analysis of hub genes were used to select reliable key genes to identify CCL19. Immunohistochemistry (IHC) was used to detect the differential expression of CCL19 in tumor tissues and adjacent tissues of breast cancer. Protein correlation analysis, signaling pathway analysis, immune infiltration analysis, gene co-expression analysis and drug sensitivity analysis of CCL19 were further used to explore the pathological clinical features and potential biological functions of CCL19. Results The expression of CCL19 was significantly increased in breast cancer. High expression of CCL19 correlates with tumor stage and predicts a better prognosis in breast cancer. The expression of CCL19 correlates with the levels of various tumor immune infiltrating cells (TILs). CCL19 has positive correlation with the expression of most immune-related genes, including immune activator, immunosuppressant, chemokine, chemokine receptor, and major histocompatibility complex (MHC) genes. Enrichment analysis showed that CCL19 was involved in immune-related pathways and PI3K-Akt signaling pathway. The above results indicate that CCL19 may modulate the prognosis of breast cancer through immune infiltration. CCL19 affects the sensitivity to chemotherapy and targeted therapy, which affects the sensitivity of TAK-715, KIN001-102 and 17-AAG. Conclusion CCL19 is overexpressed in breast cancer. CCL19 may serve as a promising biomarker for predicting breast prognosis and a candidate therapeutic target.